Drug intelligence / Profile preview

SPID-engineered GIPR antagonist antibody

Development stage: Preclinical
Lead developer: PROTEINA
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

SPID-engineered GIPR antagonist antibody is a long-acting monoclonal antibody developed by PROTEINA Co., Ltd. for the treatment of obesity and metabolic disorders. Engineered using the SPID (Surface-displayed Protein Interaction Design) platform and deep mutational scanning (DMS), the antibody is optimized for high affinity, pH-sensitive recycling, and metabolic durability. In preclinical studies using diet-induced obesity (DIO) models, the lead candidate demonstrated a 47-day half-life and superior weight loss and glycemic control compared to earlier iterations. The drug is designed to serve as a maintenance-oriented monotherapy or a foundational backbone for next-generation combination regimens in chronic weight management.

Other names: SPID-Engineered Long-Acting GIPR Antagonist Antibody

Targets

GIPR (Gastric inhibitory polypeptide receptor)GLP1R (GLP-1R)

Beyond the preview

Go deeper on SPID-engineered GIPR antagonist antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPID-engineered GIPR antagonist antibody.

Explore the full profile